How to Create a Solid Biotech Business Development Strategy is written exclusively for emerging biopharma dealmakers. With over 20 years of proven deal strategy development, Paul Brennan gives seven actionable steps to learn more about formulating and leveraging big-picture, executive buy-in, identifying and understanding your ideal partners, knowing the types of deal structures and positioning each, knowing when is the best timing for a deal, learning which tools will give the best advantage, and much, much more. It’s the perfect roadmap for serious biotech companies and dealmakers.
Download your free copy today.
Paul Brennan is Dealmaker in Residence at MotionHall. Mr. Brennan has over 20 years’ experience in Business Development and has an extensive deal sheet including M&A, in-licensing, out-licensing, regional deals and litigation resolution. Prior to consulting Mr. Brennan worked at setting business development strategies at both pharma (Astra Draco, AstraZeneca) and biotech (AnorMED, Aspreva, Tekmira, & Aquinox).
No need to pay for costly and time-consuming research. Now you can analyze thousands of companies around the globe to match your deal with MotionHall’s OutMatch. OutMatch technology brings the future to understanding the out-licensing and M&A deal market landscape in minutes. Set global match criteria for your deal(s), collaborate with your team, select potential targets, track progress, and provide key reporting analytics to your board all within OutMatch. Visit our case studies to learn more.
MotionHall is a Silicon Valley Artificial Intelligence company. Our predictive software tools help biotech companies target the best partners to get their products to market in the least amount of time. MotionHall is supported by many of the world’s most successful pharma and technology industry veterans, including advisors from Genentech, Veeva, Thomson Reuters Life Sciences, and Palantir. We are backed by Village Global, a catalyst fund backed by Bill Gates, Michael Bloomberg, and Jeff Bezos.